Bristol-Myers wins approval for 1st hepatitis C type 3 drug
NEW YORK (AP) — An experimental drug for one of the most difficult-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options for patients with the liver-destroying virus.
Daklinza (pronounced dah-KLIHN'-zah), developed by New York-based Bristol-Myers Squibb Co., is the first drug approved to treat genotype 3 hepatitis C. It's to be used with Sovaldi, one of two blockbuster hepatitis C drugs sold by Gilead Sciences, along with Harvoni.
About 10 percent of the roughly 2.7 million Americans with hepatitis C are infected with the genotype 3 strain, making it the second-most-common form.
Bristol-Myers says the list price for Daklinza, also known as daclatascir, will be $63,000 for a course of treatment, though insurers likely will seek big discounts to cover it.